Evidence map›Paper›PMID 36297407›Full record

ReviewPharmaceuticals (Basel, Switzerland)2022

Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors.

Pasquale Losurdo, Nicolò de Manzini, Silvia Palmisano, Mario Grassi, Salvatore Parisi, Flavio Rizzolio, Domenico Tierno, Alice Biasin, Chiara Grassi, Nhung Hai Truong and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Pasquale LosurdoSurgical Clinic Unit, Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
Nicolò de ManziniSurgical Clinic Unit, Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.ORCID 0000-0002-8362-9044
Silvia PalmisanoSurgical Clinic Unit, Department of Medical and Surgical Sciences, Hospital of Cattinara, University of Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
Mario GrassiDepartment of Engineering and Architecture, Trieste University, Via Valerio 6, 34127 Trieste, Italy.ORCID 0000-0002-3532-3200
Salvatore ParisiPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Pordenone, 33081 Aviano, Italy.
Flavio RizzolioPathology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Pordenone, 33081 Aviano, Italy.ORCID 0000-0002-3400-4363
Domenico TiernoDepartment of Life Sciences, Cattinara University Hospital, Trieste, Strada di Fiume 447, 34149 Trieste, Italy.
Alice BiasinDepartment of Engineering and Architecture, Trieste University, Via Valerio 6, 34127 Trieste, Italy.
Chiara GrassiDegree Course in Medicine, University of Trieste, 34100 Trieste, Italy.
Nhung Hai TruongFaculty of Biology and Biotechnology, VNUHCM-University of Science, Ho Chi Minh City 700000, Vietnam.
Gabriele GrassiDepartment of Life Sciences, Cattinara University Hospital, Trieste, Strada di Fiume 447, 34149 Trieste, Italy.ORCID 0000-0001-9704-6651
University of Trieste · ITOspedale di Cattinara · ITCa' Foscari University of Venice · ITVietnam National University Ho Chi Minh City · VN

Funding

Italian Ministry of Foreign Affairs and International Cooperation VN21GR01
6 · The paper itself

Abstract

Despite the progress made in the diagnoses and therapy of gastrointestinal cancers, these diseases are still plagued by a high mortality. Thus, novel therapeutic approaches are urgently required. In this regard, small interfering RNA (siRNA), double-stranded RNA molecules able to specifically target the mRNA of pathological genes, have the potential to be of therapeutic value. To be effective in the human body, siRNAs need to be protected against degradation. Additionally, they need to target the tumor, leaving the normal tissue untouched in an effort to preserve organ function. To accomplish these tasks, siRNAs have been formulated with smart delivery systems such has polymers and lipids. While siRNA protection is not particularly difficult to achieve, their targeting of tumor cells remains problematic. Here, after introducing the general features of gastrointestinal cancers, we describe siRNA characteristics together with representative delivery systems developed for gastrointestinal cancers. Afterward, we present a selection of research papers employing siRNAs against upper- and lower- gastrointestinal cancers. For the liver, we also consider papers using siRNAs to combat liver cirrhosis, a relevant risk factor for liver cancer development. Finally, we present a brief description of clinical trials employing siRNAs for gastrointestinal cancers.

Indexed as

delivery systemsgastro-intestinal cancerliver fibrosissiRNAs

Identifiers

PMID36297407
PMCPMC9612316
OpenAlexW4306951922

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.